• PDF / 169,491 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 10 Downloads / 142 Views

DOWNLOAD

REPORT

---

1 S

Ventricular tachycardia and off-label use: 2 case reports In a single-centre, cross-sectional study of 75 patients, who had coronavirus disease-2019 (COVID-19), were treated at the University of Health Sciences Samsun Training and Research Hospital, Turkey between 20 March 2020 and 10 April 2020, of whom, two patients [sexes and ages not stated] were described, who developed ventricular tachycardia during off-label treatment with azithromycin and hydroxychloroquine for Covid-19. Additionally, both patients also received off-label treatment with favipiravir for COVID-19 [dosages, routes, durations of treatments with reactions onsets and outcomes not stated]. Both patients were diagnosed with COVID-19 and were admitted to an ICU. Subsequently, both patients started receiving offlabel treatment with azithromycin, favipiravir and hydroxychloroquine. During ICU admission, both patients developed ventricular tachycardia. Prior to initiation of treatment, both patients had elevated Tp-e intervals and Tp-e/QTc ratios, while QTc intervals were normal. However, after treatment, further increase in Tp-e intervals, Tp-e/QTc ratios and QTc intervals were observed. Yenercag M, et al. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. Journal of Electrocardiology 62: 5-9, 803498943 Sep-Oct 2020. Available from: URL: http://doi.org/10.1016/j.jelectrocard.2020.07.005

0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 29 Aug 2020 No. 1819